Merck & Co.
AWARDS
NEWS
It was another busy week for clinical trial news. Here’s a look.
Organon is paying $75 million upfront, taking on about $9 million of Forendo debt, and up to $270 million in various development and regulatory milestones.
The first week of November was marked by numerous clinical trial announcements. Here’s a look.
Merck and Ridgeback Biotherapeutics’ antiviral drug molnupiravir, which showed great promise against COVID-19 in clinical trials, received its first authorization.
Immunology expert Constance Cullen of Schering-Plough Corp. revealed that Theranos inappropriately attached Schering-Plough’s logo to data issued to potential investors.
In November 2019, Emory realized this experimental drug could have significant potential in respiratory viruses such as COVID-19.
JOBS
IN THE PRESS